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Gene expression profiling was performed on the human neuroglial cell line T98G after
treatment with adaptogen ADAPT-232 and its constituents – extracts of Eleutherococcus
senticosus root, Schisandra chinensis berry, and Rhodiola rosea root as well as several
constituents individually, namely, eleutheroside E, schizandrin B, salidroside, triandrin, and
tyrosol. A common feature for all tested adaptogens was their effect on G-protein-coupled
receptor signaling pathways, i.e., cAMP, phospholipase C (PLC), and phosphatidylinosi-
tol signal transduction pathways. Adaptogens may reduce the cAMP level in brain cells by
down-regulation of adenylate cyclase gene ADC2Y and up-regulation of phosphodiesterase
gene PDE4D that is essential for energy homeostasis as well as for switching from cata-
bolic to anabolic states and vice versa. Down-regulation of cAMP by adaptogens may
decrease cAMP-dependent protein kinase A activity in various cells resulting in inhibition
stress-induced catabolic transformations and saving of ATP for many ATP-dependant meta-
bolic transformations. All tested adaptogens up-regulated the PLCB1 gene, which encodes
phosphoinositide-specific PLC and phosphatidylinositol 3-kinases (PI3Ks), key players for
the regulation of NF-κB-mediated defense responses. Other common targets of adap-
togens included genes encoding ERα estrogen receptor (2.9–22.6 fold down-regulation),
cholesterol ester transfer protein (5.1–10.6 fold down-regulation), heat shock protein Hsp70
(3.0–45.0 fold up-regulation), serpin peptidase inhibitor (neuroserpin), and 5-HT3 receptor
of serotonin (2.2–6.6 fold down-regulation). These findings can be reconciled with the
observed beneficial effects of adaptogens in behavioral, mental, and aging-associated dis-
orders. Combining two or more active substances in one mixture significantly changes
deregulated genes profiles: synergetic interactions result in activation of genes that none
of the individual substances affected, while antagonistic interactions result in suppression
some genes activated by individual substances. These interactions can have an influence
on transcriptional control of metabolic regulation both on the cellular level and the level of
the whole organism. Merging of deregulated genes array profiles and intracellular networks
is specific to the new substance with unique pharmacological characteristics. Presumably,
this phenomenon could be used to eliminate undesirable effects (e.g., toxic effects) and
increase the selectivity of pharmacological intervention.
Keywords: pharmacogenomics, Rhodiola rosea, Schisandra chinensis, Eleutherococcus senticosus, ADAPT-232,
salidroside, eleutheroside E, schizandrin B
INTRODUCTION
The term adaptogen was introduced in scientific literature in
the 1950s to refer to substances that increase the “state of non-
specific resistance” under stress conditions (Lazarev, 1958; Lazarev
et al., 1959). The adaptogen concept was based on the theory
of stress (Selye, 1950), initially defined as a state of threatened
homeostasis, and a general adaptation syndrome characterized
by a non-specific response of the organism to diverse stressors
(physical, emotional, environmental, etc.). It has been postulated
that adaptogens should be safe and are able to normalize body
Abbreviations: FOXO, forkhead box O; HPA, hypothalamic-pituitary-adrenal;
JNK1, c-Jun N-terminal protein kinase; NO, nitric oxide; NPY, neuropeptide Y.
functions irrespective of the nature of stressors (Brekhman II and
Dardymov, 1969). On the verge of the new millennium, the def-
inition of adaptogens was updated to “a new class of metabolic
regulators which increase the ability of an organism to adapt to envi-
ronmental factors and to avoid damage from such factors” (Panoss-
ian et al., 1999a). The concept of adaptogens is now generally
accepted by the scientific community (EMEA/HMPC/102655/,
2007; Samuelsson and Bohlin, 2009), although it has yet to gain
prominence in mainstream pharmacology. In this context recent
research progress has taken two main forms:
• Convincing clinical evidence has been generated on the efficacy
of adaptogens, based on clinical trials performed in accordance
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with the International Conference in Harmonization Regu-
lations (ICH) standards for good clinical practice (Davydov
and Krikorian, 2000; Goulet and Dionne, 2005; Sarris, 2007;
Bleakney, 2008; Panossian and Wikman, 2009, 2010; Dwyer
et al., 2011; Hung et al., 2011; Iovieno et al., 2011; Sarris et al.,
2011; Chan, 2012; Ishaque et al., 2012),
• Some key molecular mechanisms of adaptogen activity were
defined (Panossian et al., 2007, 2009, 2012).
The stress-protective activity of adaptogens is associated with
regulation of homeostasis both on:
• the system level via several mechanisms of action which are
linked to the hypothalamic-pituitary-adrenal (HPA) axis, and
the cellular level via activation of molecular chaperones, mainly
hsp70 proteins, and the regulation of key mediators of the
stress response, including neuropeptide Y (NPY), cortisol, nitric
oxide, stress-activated protein kinase JNK, and forkhead box O
transcription factor (Panossian et al., 2007, 2009, 2012; Wiegant
et al., 2009).
An important role of CNS system in stress is generally accepted,
since the stress concept has been defined by Selye (Fink, 2000).
Effect of adaptogens on CNS system, particularly neuroprotective
activity has been demonstrated in many animal and human stud-
ies (Panossian and Wikman, 2010; Panossian et al., 2011). Clinical
efficacy of adaptogens in behavioral and mental disorders such as
depression, anxiety, bipolar disorder, chronic, and stress-induced
fatigue has been recently reviewed (Panossian and Wikman, 2009,
2010).
ADAPT-232 (Chisan®) is a traditional herbal medicinal prod-
uct consisting of a fixed combination of extracts from Rhodiola
rosea root, Schisandra chinensis berry, and Eleutherococcus senti-
cosus root. It is taken for decreased body performance such as
fatigue and weakness (Bogatova et al., 1997; Narimanian et al.,
2005; Aslanyan et al., 2010). In general, herbal mixtures exert
their bioactivities through synergistic interactions of single com-
ponents. This synergism can be attributed to the fact that med-
icinal herbs contain many different phytochemicals, which may
mutually influence each other’s activity. More than 140 com-
pounds have been identified in R. rosea roots (Panossian and
Wikman, 2010), 100 compounds in E. senticosus roots (Huang
et al., 2011), and about 200 compounds in S. chinensis berries
(Panossian and Wikman, 2008). Many of them were shown to
be active in pharmacological in vivo and in vitro experiments,
and likely contribute to the activity of the total extracts (Wag-
ner et al., 1994; Panossian, 2003; Panossian and Wagner, 2005,
2011; Panossian and Wikman, 2008, 2010; Panossian et al., 2008;
Huang et al., 2011). It has been shown that the adaptogenic
activity of ADAPT-232 is associated with key mediators of stress
response, e.g., heat-shock-proteins (Hsp70) and NPY, involved in
the regulation of homeostasis, oxidative stress, energy metabo-
lism, cognitive function, and activation of the immune system
during fatigue and exhaustion (Prodius et al., 1997; Panossian
et al., 2009). However, the cellular and molecular modes of action
are not well understood due to the fact that herbal remedies
in general have multiple targets and several mechanisms rather
than a single mechanism may account for their pharmacological
effects.
Any pharmacological effect represents an integrated response
of an organism to the drug. The response can be associated with
interactions between the drug and the cell at various levels of
regulation:
• The level of a small physiologically active molecules, e.g., cAMP
plays an important role in the integrative response of the organ-
ism. This is the so-called metabolomic level, because ATP is a
precursor of cAMP and AMP is a metabolite.
• The level of proteins involved in the synthesis or degradation
of ligands or ligand receptors. This is the so-called proteomics
level of regulation.
• Genes encoding proteins involved in synthesis, degradation, sig-
nal reception, and regulation. This is the so-called genomic and
transcriptional level of regulation.
Activation or suppression of gene expression results in acti-
vation or inhibition of the biosynthesis of encoded proteins
(enzymes, cofactors, or receptors), which in turn affects the pro-
duction and function of active small molecules. Gene expression
profiles aid in tracing molecular interactions and signal transduc-
tion pathways and to predict the pharmacological effect a drug will
have on various cellular functions.
Recently, the so-called “-omics” technologies have been estab-
lished for the analysis of pharmacological effects (Ulrich-
Merzenich et al., 2007; Sarris et al., 2012). Since transcriptomics
and proteomics can monitor cellular changes in gene or pro-
tein expression upon drug treatment in a comprehensive fashion,
these techniques may be exquisitely suited to investigate the multi-
faceted mechanisms of herbal formulas. Therefore, we have ana-
lyzed the microarray-based transcriptome-wide mRNA expression
profiles of the neuroglial cell line T98G after exposure to ADAPT-
232 and its herbal components, R. rosea, S. chinensis, and E.
senticosus.
The choice of neuroblastoma cell line T98G for our study
is based on results obtained in many publications (Stein, 1979;
Guzhova et al., 2001; Su et al., 2012). In the central nervous sys-
tem, approximately 90% of the cells are glia. Glia has been shown
to have several functions, including serving as a transportation
link between the bloodstream and neurons, uptake of neurotrans-
mitters, synthesis and release of neurotrophic factors, immune
regulation, and modulation of synaptic activity (Henn and Ham-
berger, 1971; Haydon, 2001; Ullian et al., 2001). Glia contributes
to the defense of the brain through the expression of the innate
immune response, promoting the clearance of neurotoxic pro-
teins and apoptotic cells from the CNS as well as by regulating
the entry of inflammatory systemic cells into the brain at the
blood-brain barrier (Nguyen et al., 2002; Hauwel et al., 2005).
This stimulates both tissue repair and the rapid restoration of
tissue homeostasis. An important physiological function of neu-
roglial cells is metabolic supply of energy and other substances,
maintaining brain homeostasis – a function supposed to be the
characteristic for adaptogens by definition. Glial cell express a vari-
ety of hormonal receptors, which are critical during stress-induced
diseases. Glial cell express steroid receptors and generate many
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steroid hormones which elicit rapid non-genomic effects on neu-
rons via both membrane-bound G-protein coupled receptors and
nuclear genomic receptors known to activate RNA and protein
synthesis (Bennett, 2000). Guzhova et al. (2001) show that glioma
cells export Hsp70 into the culture medium whether under nor-
mal conditions or subjected to heat shock. Hsp70 can be released
by glia and that exogenous Hsp70 can enhance neuronal stress
tolerance (Guzhova et al., 2001). Finally, an ability of astrocytes,
but not neurons, to prevent macrophage and T-Cell inflammation
in the CNS, to attenuate axonal loss and gliosis resulting in neu-
roprotection in experimental autoimmune encephalomyelitis, the
most widely used mouse model of multiple sclerosis (Spencea et al.,
2011) was the reason to select neuroglia cells in our studies devoted
to understand molecular mechanisms of action of adaptogens.
The aim of the investigation was to compare similarities
and differences in gene expression profiles upon treatment with
these three adaptogenic plants. We compared the two plant
extracts ADAPT-232 and ADAPT-232 forte (which is the same
composition as ADAPT-232 except also includes the anti-stress
vitamin, calcium pantothenate). We also compared these two
fixed-composition mixtures to individual active compounds iso-
lated from these plants, namely, salidroside, triandrin, tyrosol,
eleutheroside E, and schizandrin B (Figure 1). This pharma-
cogenomic analysis facilitates increased understanding of the
molecular modes of action of adaptogens and the synergism of
ADAPT-232 forte.
MATERIALS AND METHODS
DRUGS AND CHEMICALS
Eleutheroside E, schizandrin B, salidroside, and tyrosol, were pur-
chased from Chromadex (Irvine, CA, USA). Triandrin was isolated
in Swedish Herbal Institute (SHI) Research and Development
(Göteborg, Sweden), and identified by comparison (HPLC, TLC,
UV) with the authentic reference sample kindly provided by Prof.
Zapesoznaya (Institute of Officinal and Aromatic plants VILAR,
Moscow, Russia). Pharmaceutical grade standardized extracts of R.
rosea L. roots, E. senticosus (Rupr. et Maxim) Harms roots, and S.
chinensis (Turcz.) Baill. berries, were manufactured in accordance
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FIGURE 1 | Experimental setting for microarray-based transcriptome-wide mRNA profiling and 3D-HPLC fingerprint of ADAPT-232.
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to ICH Q7A and EMEA guidelines for Good Agricultural and
Collecting Practice (GACP) and Good Manufacturing Practice
(GMP) of active pharmaceutical ingredients (API). We have pre-
viously described the detailed composition and chemical charac-
terization of ADAPT-232 and ADAPT-232 forte (Panossian et al.,
2009, 2012; Aslanyan et al., 2010). The content of plant extracts
and their active markers was the same in both adaptogen prepara-
tions; the only difference was the presence of calcium pantothenate
in ADAPT-232 forte. Working samples used in experiments were
prepared by dilution of stock solutions (5 mg/mL) of ADAPT-232,
ADAPT-232 forte, Radix Eleutherococci genuine extract, Radix
Rhodiola genuine extract, Fructus Schisandrae genuine extract
or 10 mM solutions of purified analytical markers – salidroside
(3 mg/mL), triandrin (3.1 mg/mL), eleutheroside E (7.4 mg/mL),
schizandrin B (4 mg/mL), or tyrosol (1.4 mg/mL) with appropri-
ate volumes of phosphate buffered saline solution (PBS). Working
solutions of 200µL were added to 3 mL of cell culture to obtain the
same final concentrations of active markers and genuine extract
as in the incubation media of ADAPT-232 and ADAPT-232 forte
(Table 1). An exception was test sample B, where the concentration
was 100-fold lower than in test sample A.
The dose of 300µg/mL (final concentration of ADAPT-232
forte in incubation media) is based on the results of a recent phar-
macokinetic study of R. rosea-derived salidroside in human blood
plasma, where we measured concentrations of ∼1µg/mL= 3µM
(Panossian et al., 2010). However, in recent in vitro experiments,
an up-regulation of HSF1, Hsp72, and NPY was observed at 100-
fold lower concentrations of ADAPT-232 forte (Panossian et al.,
2012). Therefore, in the present investigation ADAPT-232 forte
was tested in two concentrations, 300 and 3µg/mL (Table 1).
The concentrations of the total extracts of three herbal ingre-
dients and their active constituents are compatible is all test
samples: e.g., final concentration of salidroside is the same –
3µM (900µg/L) in all test samples containing salidroside, namely
in Rhodiola extract, ADAPT-232, and ADAPT-232 forte. Sim-
ilarly – schizandrin B, eleutheroside E triandrin, and tyrosol,
their concentrations were calculated based of the results of
HPLC analysis of their content in genuine extracts and their
combinations. The concentrations of genuine extracts have been
Table 1 | Concentrations used to treatT98G neuroglial cells for
microarray experiments.
Drug Concentration Designation
ADAPT-232 forte 300µg/mL Test sample A
ADAPT-232 forte 3µg/mL Test sample B
ADAPT-232 172µg/mL Test sample C
Eleutherococcus extract 30µg/mL Test sample D
Schisandra extract 100µg/mL Test sample E
Rhodiola extract 40µg/mL Test sample F
Eleutheroside E 0.67µM Test sample G
Schisandrin B 5µM Test sample H
Salidroside 3µM Test sample I
Triandrin 1.5µM Test sample J
Tyrosol 3µM Test sample K
calculated using specifications of their combinations (ADAPT-
232 and ADAPT-232 forte) to ensure that they corresponds to
therapeutically effective doses.
CELL CULTURE
The human neuroglial cell line T98G was purchased from the
American Type Culture Collection (ATCC, CRL-1690). Cells were
grown in DMEM+GlutaMAX-I (Gibco, Darmstadt, Germany)
with 10% fetal bovine serum (Gibco, Darmstadt, Germany) and
1% penicillin/streptomycin (Gibco, Darmstadt, Germany). They
were passaged twice a week and maintained in a 37˚C incubator
in a humidified atmosphere with 5% CO2. All experiments were
conducted using cells in the logarithmic growth phase.
DRUG TREATMENT
T98G cells were seeded 24 h before treatment on 6-well plates in
a density of 150,000 cells per well. The next day, old medium was
removed and cells were treated in a final volume of 3 mL (Table 1).
The ethanol content was 0.8% for cells treated with isolated
compounds and vehicle-treated control cells (test sample Z). Two
technical replicates were performed for each sample. Cells were
incubated with the test substances for 24 h at 37˚C and then
subjected to RNA isolation.
mRNA ISOLATION AND QUALITY CONTROL
Cells were harvested after 24 h of treatment. Total RNA was isolated
using InviTrap Spin Universal RNA Mini kit (Stratec Molecular,
Berlin, Germany) and dissolved in RNAse free-water. The RNA
of the two technical replicates was pooled (1:1) resulting in one
sample for each treatment/control. The quality of total RNA was
checked by gel analysis using the Total RNA Nano chip assay on
an Agilent 2100 Bioanalyzer (Agilent Technologies GmbH, Berlin,
Germany). All samples were of highest quality with RIN values
of 10.
GENE EXPRESSION PROFILING
Microarray hybridizations were performed at the Institute of Mol-
ecular Biology (Mainz, Germany). Whole Human Genome RNA
chips (860K Agilent ) were used for gene expression profiling. Probe
labeling and hybridization procedures were carried out following
the One-Color Microarray-Based Gene Expression Analysis Proto-
col1. Briefly, total RNA was labeled and converted to cDNA. Then,
fluorescent cRNA (Cyanine 3-CTP) was synthesized and purified
using the QIAgen RNeasy Kit. After fragmentation of the cRNA,
samples were hybridized for 17 h at 65˚C. Microarray slides were
washed and scanned with the Agilent Microarray Scanning system.
Images were analyzed and data was extracted. The background was
subtracted and data was normalized using the standard procedures
of Agilent Feature Extraction Software.
MICROARRAY DATA ANALYSIS
Expression data was further analyzed using Chipster software2 to
filter genes by varying expression and significance. These steps
1http://www.chem.agilent.com/Library/usermanuals/Public/G414090040_
GeneExpression_One-color_v6.5.pdf
2http://chipster.csc.fi/
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include filtering genes to isolate those that were up- or down-
regulated by one to three times the standard deviation (depend-
ing on the total number of extremely up- or down-regulated
genes). A subsequent assessment of significance using empiri-
cal Bayes t -test further narrowed the pool of genes. All genes
further considered showed a significant difference from the con-
trol with p-value< 0.05, or otherwise are noted. Finally, filtered
data was used in Ingenuity pathway analysis for Core analysis, in
order to determine networks and pathways influenced by the drug
treatments3.
REAL-TIME RT-PCR
Validation of the microarray data was done by real-time RT-PCR
for five selected genes which were tested for two drug-treated
samples (Tables 2 and 3). PCR primers were designed using
Roche Universal Probe Design4 and GenScript Real-Time PCR
Primer Design5 tools. Amplification specificities were checked
with Primer Blast6 using the sequence data from the NCBI RefSeq
Human mRNA data base. Primer nucleotide sequences and used
primer concentrations are shown in Table 2. Oligonucleotides
were synthesized by MWG Eurofins. Extracted RNA was converted
to cDNA with RevertAid H Minus First Strand cDNA Synthesis Kit
(Thermo Scientific). Real-time RT-PCR experiments were per-
formed with the Roche Bio-Rad CFX384 real-time PCR detection
system. Total reaction volume was 20µL. About 4µL 5x Hot Start
Taq EvaGreen qPCR Mix (no ROX; Axon), 75–250 nM final primer
concentration, and about 500 ng RNA (converted to cDNA) were
used per reaction. The protocol was as follows: 50, 0˚C for 2 min,
95, 0˚C for 10 min, 45 cycle of 95, 0˚C for 15 s, Annealing Tem-
perature for 1 min, 72, 0˚C for 1 min and 95, 0˚C for 1 min. The
housekeeping gene RPS13 served as reference for standardization.
All measurements were done in duplicates to calculate mean values
and standard deviations. Standardized Ct (cycle threshold) values
for the genes in samples were obtained by dividing the Ct values
of genes in drug-treated samples by Ct values of RPS13 gene and
3http://www.ingenuity.com/
4http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000
5https://www.genscript.com/ssl-bin/app/primer
6http://www.ncbi.nlm.nih.gov/tools/primer-blast
multiplying with the Ct value of RPS13 in the control. Fold changes
were calculated with the∆Ct (Standardized Ct of the gene in drug-
treated sample – Ct of the gene in untreated sample) method where
the fold change is equal to 2−∆Ct for the up-regulated genes and
−(2−∆Ct ) for the down-regulated genes.
The correlation coefficient between mRNA expression values
determined by microarray hybridization and real-time RT-PCR
was R= 0.81 (Pearson Correlation Test), Table 3.
RESULTS
A microarray-based transcriptome-wide mRNA expression analy-
sis was performed to identify possible targets of the tested sub-
stances in T98G cells. T98G cells were treated with test substances
for 24 h in two technical replicates before total RNA was isolated
and pooled for microarray hybridization. Significantly deregulated
genes were identified compared to untreated controls (p< 0.05) by
means of Chipster software analysis. Ingenuity Pathway analyses
were performed with data sets of significantly up- or down-
regulated genes: 536 genes for ADAPT-232 forte, 777 genes for
ADAPT-232 forte tested at the low concentration, 534 genes for
ADAPT-232 at the higher concentration, 591 genes for Eleuthe-
rococcus extract, 599 genes for Schisandra extract, 561 genes for
substance Rhodiola extract, 567 genes for eleutheroside E, 620
genes for schizandrin B, 640 genes for salidroside, 601 genes for
triandrin,and 562 genes for tyrosol. TheVenn diagrams in Figure 2
shows the number of unique deregulated genes for each treatment
extract in comparison to the number of common deregulated
genes. Table 4 shows the main cellular functions and networks
most significantly affected by various adaptogens. Tables 5 and 6
show genes up- or down-regulated by adaptogens.
To exemplarily validate the microarray-based mRNA expres-
sions, real-time RT-PCR reactions were performed for five genes
using each two different pairs of treated and untreated sam-
ples. The expression of these genes were quantified and the
ratios between treated and untreated samples were calculated and
compared to the ratios obtained from microarray experiments
(Table 3). The correlation coefficient between mRNA expres-
sion values determined by microarray hybridization and real-time
RT-PCR was R= 0.81, indicating a high degree of concordance
between results obtained by both methods.
Table 2 | Primer nucleotide sequences and used primer concentrations.
Target gene Sequence Concentration (nM) Annealing temperature (˚C)
ADCY2 Fw: 5′-CTGCTCGCCGTCTTCTTCGCG-3′ 125 57.9
Rev: 5′-CGCCAGGGCAGTTGGAACTGTTAT-3′
CETP Fw: 5′-GAGACTGCCAAGGTGATCCAGA-3′ 125 58
Rev: 5′-GTGGTGTAGCCATACTTCAGGG-3′
ESR1 Fw: 5′-CACCCAGGGAAGCTACTGTTTG-3′ 125 58
Rev: 5′-ATCTCCACCATGCCCTCTACAC-3′
HTR3D Fw: 5′-TGACTGTTCTGCTGGGCTACA-3′ 125 58
Rev: 5′-GCGAAGTAGACACCTCGCTT-3′
PDE4D Fw: 5′-GAATCAGAGAACATTCAACGACCAACCAG-3′ 75 63.4
Rev: 5′-GCAGATGTGCCATTGTCCACATCAAAA-3′
RPS13 Fw: 5′-GGTTGAAGTTGACATCTGACGA-3′ 250 57.9–63.4
Rev: 5′-CTTGTGCAACACATGTGAAT-3′
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Table 3 | Validation of microarray-based mRNA expression by quantitative real-time RT-PCR.
Gene Sample Method Untreated cells Treated cells FC (log) FC
ADCY2 ADAPT-232 forte* Microarray 1,00 1,00 0 1,00
Real-time RT-PCR 1,08
Schisandra extract Microarray 1,00 1,00 0 1,00
Real-time RT-PCR 1,04
CETP ADAPT-232 forte* Microarray 1,00 1,00 0 1,00
Real-time RT-PCR 1,52
Eleutherococcus extract Microarray 8,75 6,13 −2,62 −6,15
Real-time RT-PCR −1,21
ESR1 ADAPT-232 forte** Microarray 8,23 4,63 −3,60 −12,13
Real-time RT-PCR −1,74
ADAPT-232 forte* Microarray 1,00 1,00 0 1,00
Real-time RT-PCR 1,42
HTR3D Eleutherococcus extract Microarray 6,93 5,65 −1,28 −2,43
Real-time RT-PCR −2,75
Salidroside Microarray 6,93 4,21 −2,72 −6,59
Real-time RT-PCR −2,81
PDE4D ADAPT-232 Microarray 1,00 1,00 0 1,00
Real-time RT-PCR 1,44
Rhodiola extract Microarray 4,84 6,85 2,01 4,03
Real-time RT-PCR 2,91
*Concentration 3µg/mL, **Concentration 300µg/mL.
FIGURE 2 | Venn diagrams of deregulated genes induced by the
treatment of neuroglial cells with Rhodiola rosea root, Schisandra
chinensis berries, and Eleutherococcus senticosus root extracts alone
and their fixed combination, ADAPT-232. (A) The number of unique
genes deregulated by each extract alone and the number of deregulated
genes that overlapped multiple extracts. (B) Pool of all genes whose
expression was affected by any of the three extracts alone in comparison
to ADAPT-232.
DISCUSSION
Based on the analysis of results obtained in this study, we can draw
several conclusions discussed in detail below.
THE EFFECT OF ADAPTOGENS ON MEMBRANE-BOUND
G-PROTEIN-COUPLED RECEPTORS
A common feature of all drugs tested is their effect on G-
protein-coupled receptor (GPCR) signaling pathways. All tested
adaptogens significantly deregulated the expression of a large
number of genes encoding (a) GPCRs (Table 5) and (b)
key proteins of G-protein downstream pathways, i.e., cAMP,
phospholipase C (PLC), and phosphatidylinositol mediated signal
transduction (Table 6; Figure 3).
G-protein-coupled receptors (Gilman, 1987; Foord et al.,
2005) are involved in a wide variety of physiological processes
(Wettschureck and Offermanns, 2005; Hazell et al., 2011)
including:
• Regulation of behavior and mood including binding of
neurotransmitters such as serotonin, dopamine, GABA, and
glutamate.
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Table 4 | Cellular functions associated with genes and genetic
networks that showed significant differences in expression after
treatment with the test samples.
Functions Test samples
Antigen presentation Low concentration of ADAPT-322 forte
Cancer Tyrosol
Carbohydrate metabolism Eleutheroside E
Cell cycle Salidroside
Cell death ADAPT-232 forte, schizandrin B, tyrosol
Cell growth and proliferation ADAPT-232
Cell–cell signaling and interaction ADAPT-232 forte, Schisandra extract,
schizandrin B, ADAPT-232, Rhodiola
extract, eleutheroside E
Cellular assembly and
organization
Low concentration of ADAPT-322 forte,
schizandrin B
Cellular compromise Schizandrin B
Cellular development ADAPT-232, Rhodiola extract,
Schisandra extract
Cellular movement ADAPT-232, ADAPT-232 forte,
salidroside
Inflammatory disease Triandrin
Lipid metabolism All tested substances except
schizandrin B
Molecular transport Triandrin, tyrosol
Nervous system development
and function
Tyrosol
Neurological disease Salidroside
Nucleic acid metabolism Eleutherococcus extract
Small molecule biochemistry Eleutherococcus extract, Schisandra
extract, Rhodiola extract, eleutheroside
E, triandrin, tyrosol
Vitamin and mineral metabolism Schisandra extract
• Sympathetic and parasympathetic nervous systems, which are
regulated by GPCR pathways, and are responsible for control
of many automatic body functions such as regulating blood
pressure, heart rate, and digestive processes.
• Regulation of immune system activity and inflammation
• Neuroendocrine homeostasis modulation.
All of these physiological processes are associated with stress
and adaptogen activity, which increases stress tolerance.
The regulation of GPCRs is thought to play a fundamental role
in maintaining physiologic homeostasis during stress (Carman
and Benovic, 1998). A number of pathologic states are associ-
ated with disturbances in the functional activity of certain GPCRs
(Lefkowitz, 1996). GPCRs are extremely important targets for
neuropsycho-pharmacology (Roth et al., 1998). Many neuropsy-
chiatric drugs either bind directly to specific GPCRs (e.g., antipsy-
chotics) or affect GPCRs indirectly by influencing the amount of
available native agonist (e.g., antidepressants; Von Zastrow, 2002).
Table 6 shows that adaptogens down-regulated the HTR1A
gene encoding the 5-HT3 GPCR, which is known to activate
an intracellular second messenger cascade resulting in excitatory
or inhibitory neurotransmission (Hoyer et al., 1994). Activation
of serotonin receptors modulate the release of many neuro-
transmitters including glutamate, GABA, dopamine, epineph-
rine/norepinephrine, and acetylcholine, as well as many hormones
including oxytocin, prolactin, vasopressin, cortisol, corticotropin,
substance P, and others. Activation of serotonin receptors also
influence various biological and neurological processes such as
aggression, anxiety, appetite, cognition, learning, memory, mood,
nausea, sleep, and thermoregulation. A variety of pharmaceuti-
cal agents and illicit drugs, including many antidepressants and
antipsychotics, target serotonin receptors (Yakel, 2000; Kennett
et al., 1997). The binding of serotonin to the 5-HT3 receptor in
neuronal cells of the central (e.g., brain-stem cells) and peripheral
nervous systems opens the membrane channels, which in turn
leads to an excitatory response and anxiety (Kennett et al., 1997).
Thus, the observed down-regulation of the HTR1A gene by tyrosol
(Table 6) is in line with publications that have demonstrated the
anti-depressive effects of tyrosol in rats (Wikman and Panossian,
2004; Panossian et al., 2008) and recent publications showing that
Rhodiola extracts affect serotonin receptors (Chen et al., 2009b;
Mannucci et al., 2012). Serotonin receptors are also known to reg-
ulate longevity (Murakami and Murakami, 2008) and behavioral
aging (Murakami et al., 2008) in the nematode Caenorhabditis
elegans. This agrees with several publications demonstrating the
beneficial effects of R. rosea on the lifespan of C. elegance and the
fruit fly, Drosophila melanogaster (Jafari et al., 2007; Wiegant et al.,
2009).
G-protein-coupled lysophospholipid receptors regulate cellu-
lar Ca2+ homoeostasis, cytoskeletal architecture, proliferation
and survival, migration, and adhesion. They have been impli-
cated in development; regulation of the cardiovascular; immune
and nervous systems; inflammation; arteriosclerosis; and cancer.
Lysophospholipid receptor ligands bind to and activate their corre-
sponding transmembrane receptors. The activated receptors have
a wide range of cellular effects depending on which ligand, recep-
tor, and cell-type is involved. Primary effects include inhibition
of adenylyl cyclase and release of calcium from the endoplasmic
reticulum, while secondary effects include preventing apoptosis
and increasing cell proliferation (Meyer zu Heringdorf and Jakobs,
2007). Down-regulation of GPCRs by adaptogens (Table 6) indi-
cates that the number of receptors is greatly reduced leading
to strongly attenuated signal transduction via G-proteins and
their effectors (Von Zastrow, 2002), which may contribute to the
beneficial effect of adaptogens in stress-related disorders.
G-protein-coupled receptor expression and G-protein-
mediated signal transduction are affected by age and play an
important role in the development of the major human patholo-
gies associated with aging, cancer, neurodegenerative disorders,
and cardiovascular diseases (Joseph et al., 1993; Alemany et al.,
2007). This supports the results of in vivo studies in rats show-
ing that ADAPT-232 has potential value for the treatment of
age-related disorders of the stress system and may be effective
in maintaining the health in elderly individuals (Makarov et al.,
2007). ADAPT-232 counters effects of aging associated with:
• deregulation of programmed cell death (apoptosis),
• suppression of the immune system and spontaneous tumors
promotion,
www.frontiersin.org February 2013 | Volume 7 | Article 16 | 7
Panossian et al. Gene expression profiles of ADAPT-232
Ta
b
le
5
|G
en
es
u
p
-
an
d
d
ow
n
-r
eg
u
la
te
d
by
ad
ap
to
ge
n
s
in
T
98
G
ce
lls
.
G
en
es
G
en
es
fa
m
ily
Li
ga
n
d
A
D
A
P
T-
23
2
fo
rt
e
(3
00
m
g
/L
)
A
D
A
P
T-
23
2
fo
rt
e
(3
m
g
/L
)
A
D
A
P
T-
23
2
E
le
u
th
er
o
co
cc
u
s
ex
tr
ac
t
S
ch
is
an
d
ra
ex
tr
ac
t
R
h
o
d
io
la
ex
tr
ac
t
E
le
u
th
er
o
si
d
e
E
S
ch
iz
an
d
ri
n
B
S
al
id
ro
si
d
e
Tr
ia
n
d
ri
n
Ty
ro
so
l
G
P
R
1
O
rp
ha
n
−3
,2
94
G
P
R
4
S
P
C
/L
P
C
ly
so
P
L
51
,2
68
3,
48
2
G
P
R
6
or
ph
an
A
1
sp
hi
ng
os
in
e
1P
−3
,4
34
G
P
R
12
or
ph
an
A
1
sp
hi
ng
os
in
e
1P
86
,8
23
4,
08
4
4,
28
7
3,
34
0
G
P
R
17
O
rp
ha
n
12
5,
36
6
−2
,4
62
−2
,4
45
−2
,6
76
−2
,9
90
−2
,6
39
−2
,6
76
G
P
R
18
O
rp
ha
n
−3
,5
55
−6
,5
89
−4
,1
70
−3
,5
55
G
P
R
22
O
rp
ha
n
−2
,4
12
G
P
R
37
or
ph
an
A
4
−6
,2
33
−3
,4
11
−2
,9
69
−5
,4
64
−2
,6
39
−3
,4
11
−5
,2
05
−4
,1
41
G
P
R
55
O
rp
ha
n
−2
,5
14
−3
,2
94
G
P
R
52
O
rp
ha
n
A
2
19
0,
01
9
G
P
R
61
O
rp
ha
n
12
6,
23
8
G
P
R
65
S
P
C
/L
P
C
−6
,8
69
−3
,0
95
G
P
R
78
O
rp
ha
n
A
3
−1
1,
95
9
G
P
R
82
O
rp
ha
n
−2
,9
90
G
P
R
83
O
rp
ha
n
A
9
−2
,6
39
2,
77
0
−7
,2
10
G
P
R
85
O
rp
ha
n
S
R
E
B
−2
,4
79
G
P
R
88
O
rp
ha
n
−2
,9
90
−2
,7
70
−2
,6
57
G
P
R
10
1
O
rp
ha
n
−2
,4
28
G
P
R
11
0
LN
B
7T
M
−8
,7
54
G
P
R
11
1
LN
B
7T
M
6,
54
3
2,
28
2
2,
39
5
3,
05
3
G
P
R
11
4
LN
B
7T
M
−5
,6
57
G
P
R
11
2
LN
B
7T
M
−3
,6
30
−3
,9
18
−2
,9
28
−3
,9
72
−2
,2
82
−4
,5
63
G
P
R
12
8
LN
B
7T
M
3,
68
1
3,
55
5
2,
90
8
5,
24
2
3,
89
1
2,
90
8
3,
05
3
3,
45
8
G
P
R
14
1
O
rp
ha
n
5,
54
0
2,
75
1
6,
82
1
4,
59
5
2,
69
4
4,
28
7
G
P
R
14
8
O
rp
ha
n
3,
97
2
3,
01
0
3,
41
1
6,
27
7
3,
53
1
3,
24
9
3,
45
8
5,
20
5
G
P
R
15
0
O
rp
ha
n
3,
31
7
G
P
R
15
1
O
rp
ha
n
−2
,6
39
−6
,8
69
G
P
R
16
0
O
rp
ha
n
−3
,4
34
G
P
R
17
1
O
rp
ha
n
−3
,4
34
G
P
R
17
9
2,
31
3
−2
,3
29
G
P
R
18
2
2,
34
6
G
P
R
C
6A
C
al
ci
um
se
ns
or
2,
26
6
3,
97
2
6,
40
9
9,
44
8
3,
09
5
3,
91
8
3,
58
0
3,
83
7
G
P
R
37
L1
O
rp
ah
n
A
6
2,
88
8
H
TR
1F
5-
H
TA
S
er
ot
on
in
3.
4
H
TR
1A
5-
H
TA
S
er
ot
on
in
−2
.9
G
R
M
6
M
et
ab
ot
ro
pi
c
gl
ut
am
at
e
G
lu
ta
m
at
e
2.
3
2.
5
3.
1
3.
0
2.
7
2.
5
3.
5
Th
e
va
lu
es
sh
ow
fo
ld
ch
an
ge
s
co
m
pa
re
d
to
th
e
co
nt
ro
l.
Frontiers in Neuroscience | Neuroendocrine Science February 2013 | Volume 7 | Article 16 | 8
Panossian et al. Gene expression profiles of ADAPT-232
Ta
b
le
6
|C
o
m
m
o
n
ge
n
es
u
p
-
an
d
d
ow
n
-r
eg
u
la
te
d
by
ad
ap
to
ge
n
s
an
d
co
rr
es
p
o
n
d
in
g
p
ro
te
in
s
in
T
98
G
ce
lls
.
G
en
e
an
d
co
rr
es
p
o
n
d
in
g
p
ro
te
in
A
D
C
Y
2
ad
en
yl
at
e
cy
cl
as
e
P
D
E
4D
p
h
o
sp
h
o
-
d
ie
st
er
as
e
P
I3
K
C
2G
p
h
o
sp
h
at
id
yl
in
o
si
to
l-
3
-k
in
as
e
P
IK
3
P
R
K
C
G
an
d
P
R
K
C
Z
p
ro
te
in
ki
n
as
e
C
P
LC
B
1
p
h
o
sp
h
o
lip
as
e
C
b
et
a
1
(p
h
o
sp
h
o
in
o
si
ti
d
e-
sp
ec
ifi
c)
P
LC
D
4
p
h
o
sp
h
o
lip
as
e
C
*
C
E
T
P
ch
o
le
st
er
o
l
et
h
er
tr
an
s
E
S
R
1
es
tr
o
ge
n
re
ce
p
to
r
1
S
E
R
P
IN
A
**
S
E
R
P
IN
B
**
H
T
R
3D
5-
H
T
3
re
ce
p
to
ro
f
se
ro
to
n
in
H
S
PA
1B
h
ea
t
sh
o
ck
p
ro
te
in
72
FO
X
A
1
A
D
A
P
T-
23
2
fo
rt
e
(3
00
µ
g/
m
L)
−2
.8
+4
.3
+5
.1
+4
.7
−6
.1
−8
.9
−1
2.
0
A
3
−4
.4
−4
.3
A
D
A
P
T-
23
2
(1
72
µ
g/
m
L)
−2
.9
+6
.1
+3
.7
−1
2.
7
−7
.6
−1
9.
3
A
1
+
9.
3
B
9
−3
.3
E
le
ut
he
ro
co
cc
us
(3
0
µ
g/
m
L)
−2
.4
+5
.0
+2
.7
+3
.7
−1
3.
2
−6
.1
−2
2.
6
A
1
+
2.
7
B
2
−3
.3
B
4
−3
.1
−2
.2
3.
0
+6
.9
S
ch
is
an
dr
a
(1
00
µ
g/
m
L)
+2
.7
+7
.2
+4
.4
−9
.6
−5
.1
−5
.8
A
1
+
3.
6
B
2
−2
.4
B
3
−3
.3
−3
.4
R
ho
di
ol
a
(4
0
µ
g/
m
L)
−3
.7
+4
.0
+6
.6
−5
.1
−9
.8
−7
.5
A
1
+
12
.7
B
2
−4
.5
B
4
−3
.4
B
9
−4
.2
+3
.3
E
le
ut
he
ro
si
de
E
(0
.6
7
µ
M
)
+3
.2
+3
.1
−1
0.
1
−8
.3
−7
.1
B
9
−2
.7
−2
.2
S
ch
is
an
dr
in
B
(5
µ
M
)
+3
.2
+4
.1
−1
0.
6
−3
.4
P
4 −2
1.
7
S
al
id
ro
si
de
(3
µ
M
)
−2
.8
+4
.2
+5
.0
−1
0.
1
−6
.3
−3
.0
A
1
+
5.
4
B
2
−4
.3
−6
.6
+3
.3
Tr
ia
nd
rin
(1
.5
µ
M
)
+3
.4
−5
.1
−9
.5
−2
.9
A
1
+
6.
5
B
2
−3
.0
B
4
−2
.4
+3
.6
R
B
FO
X
1
FO
X
1−
2.
5
Ty
ro
so
l(
3
µ
M
)
−3
.1
+4
.6
+3
.0
−9
.9
−5
.9
−6
.6
B
9
−2
.6
−6
.3
A
D
A
P
T-
23
2
fo
rt
e
(3
µ
g/
m
L)
A
D
C
Y
4
+9
6.
3
+6
7.
2
A
7
+
13
2.
5
+4
4.
0
+4
40
+
44
.5
+1
15
.4
A
10
+
38
.3
B
8
+4
4.
9
Th
e
va
lu
es
sh
ow
fo
ld
ch
an
ge
s
co
m
pa
re
d
to
co
nt
ro
l.
(+
)I
nd
ic
at
es
up
-r
eg
ul
at
io
n.
(−
)I
nd
ic
at
es
do
w
n-
re
gu
la
tio
n.
*P
LC
D
4
ex
pr
es
si
on
is
a
m
ar
ke
rf
or
ca
nc
er
.*
*E
ffe
ct
s
of
P
K
C
ar
e
ce
ll-
ty
pe
sp
ec
ifi
c:
in
C
N
S
ac
tiv
at
io
n
of
P
K
C
w
as
as
so
ci
at
ed
w
ith
ne
ur
on
al
ex
ci
ta
tio
n
(5
-H
T)
an
d
m
em
or
y.
**
A
1-
A
10
an
d
B
2-
B
9
re
pr
es
en
tt
he
di
ffe
re
nt
is
of
or
m
s
of
th
e
S
E
R
P
IN
s.
www.frontiersin.org February 2013 | Volume 7 | Article 16 | 9
Panossian et al. Gene expression profiles of ADAPT-232
FIGURE 3 | Hypothetic molecular mechanisms by which adaptogens
activate adaptive stress response pathways. Neurons normally receive
signals from multiple extracellular stressors that activate adaptive cellular
signaling pathways, e.g., many neurotransmitters activate GTP-binding protein
coupled receptors (GPCR). The receptors in turn activate kinase cascades
including those that activate protein kinase C (PKC), activate protein kinase A
(PKA), and phosphatidylinositol-3-kinase (PI3K). Effect of adaptogens on
G-protein-coupled receptors pathways: up-regulated genes are represented in
red, down-regulated in blue color. The Gs alpha subunit (or Gs protein)
activates the cAMP-dependent pathway by activating adenylate cyclase. Gi
alpha subunit (or Gi/G0 or Gi protein) inhibits the production of cAMP from
ATP. DAG, diacylglycerol; IP3, inositol triphosphate; PLC, phospholipase C.
• decrease in liver detoxification,
• CNS malfunction (loss of memory and learning ability), and
the development and progression of cardiac insufficiency, and
hypercholesterolemia.
THE EFFECT OF ADAPTOGENS ON cAMP-MEDIATED G-PROTEIN
SIGNALING PATHWAYS
Taking into account that adaptogens down-regulated the expres-
sion of genes encoding adenylate cyclase and up-regulated gene
expression for phosphodiesterase, we suggest that adaptogens
reduce the cAMP level in brain cells by (a) inhibiting adeny-
late cyclase (inhibiting synthesis of cAMP) and (b) stimulating
phosphodiesterase (stimulating degradation of cAMP; Figure 3).
Protein kinase A (PKA) acts in a cAMP-dependent manner
(Walsh and Van Patten, 1994). Low levels of cAMP down-regulate
PKA activity. PKA has several cellular functions including regula-
tion of glycogen, sugar, and lipid metabolism. The effects of PKA
activation vary with the cell-type, e.g., in adipocytes PKA stimu-
late lipases while in myocytes (skeletal muscle) and hepatocytes
PKA increases glucose formation (by stimulating glycogenolysis
and inhibiting glycogenesis) and its catabolic transformation
to pyruvate (glycolysis). This provides free energy in the form
of ATP and NADH, which play an important role in stress
response.
The regulation of cAMP levels and PKA activity is a key
mechanism of energy homeostasis and represents a metabolic
switch between catabolism and anabolism (Walsh and Van Pat-
ten, 1994; Conti, 2000; Abramovitch et al., 2004; Vandamme
et al., 2012). Down-regulation of cAMP and PKA by adapto-
gens decreases stress-induced catabolic transformations. PKA is
presumably responsible for the stress-induced protective energy-
saving effects of adaptogens. This energy-saving effect favors ATP-
consuming anabolic transformations. Indeed, the inhibition of
adenylate cyclase by adaptogens can increase intracellular ATP
levels and prevent ATP from being converted to cAMP (Taussig
and Gilman, 1995). This increased store of ATP might represent
an energy source for other ATP-dependent enzymatic reactions
required for metabolism.
Mitochondrial decay is a major cause of aging, leading to
the subsequent death of aerobic organisms including humans.
Impairments in mitochondrial antioxidant status were invariably
associated with decreased mitochondrial ATP-generation capacities
as well as with increases in mitochondria-driven reactive oxygen
species (ROS) production in all tested tissues.
Long-term supplementation of male and female C57BL/6J
mice (starting from the age of 36 weeks) with schizandrin
B (administered at 0.012%, w/w) enhanced mitochondrial ATP-
generation capacity in various tissues (brain, heart, liver, and
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kidney) during aging and mitigated age-dependent impairments
in mitochondrial antioxidant capacity and functional ability,
thereby retarding the aging process in mice, particularly during
early aging, up to the age of 120 weeks (Ko et al., 2008). Schizandrin
B was shown to increase the intracellular ATP levels and to protect
against Gentamicin and Cyclosporine A-induced nephrotoxicity
by decreasing oxidative stress and cell death in vitro and in vivo
(Chiu et al., 2008; Zhu et al., 2012). R. rosea extract activated the
synthesis or resynthesis of ATP in skeletal muscles mitochondria
and stimulated reparative energy processes after intense exercise in
rats. Treatment with R. rosea extract significantly (by 24.6%) pro-
longed the duration of exhaustive swimming in comparison with
control rats (Abidov et al., 2003). Salidroside was shown to signif-
icantly increase the rate of ATP in isolated keratinocyte (Delepee
et al., 2004). These studies are in line with our hypothesis on the
mechanism of ATP-generation by adaptogens and their potential
benefits in fatigue and aging-related diseases.
The brain’s prefrontal cortex cells are known to contain
hyperpolarization-activated channels that can open when they
are exposed to cAMP in stress. Excessive opening of these chan-
nels impairs cognitive function. It has been suggested that cAMP
inhibitors can inactivate the channels allowing for normal neu-
ron function. This reconnects the hyperpolarized cells to the
neural network, and thus improves working memory, which plays
a key role in abstract thinking, planning, organizing, etc. (Wang
et al., 2007; Arnsten, 2011). Adaptogens may help in therapies
for cognitive deficits associated with normal aging, and for cog-
nitive changes associated with schizophrenia, bipolar disorder,
or attention deficit hyperactivity disorder (ADHD; Wang et al.,
2011).
This hypothesis is in accordance with our findings and publica-
tions,where ADAPT-232 and other adaptogens have demonstrated
beneficial effects on cognitive function in humans (Bogatova et al.,
1997; Hartz et al., 2004; Narimanian et al., 2005; Darbinyan et al.,
2007; Fintelmann and Gruenwald, 2007; Weng et al., 2007; Ols-
son et al., 2009; Aslanyan et al., 2010; Panossian and Wikman,
2010; Edwards et al., 2012). Two clinical pilot studies showed that
ADAPT-232 significantly improved attention and increased speed
and accuracy during stressful cognitive tasks in comparison to a
placebo control (Aslanyan et al., 2010). ADAPT-232 significantly
decreased the number of mistakes made by test subjects in com-
plicated psychometric tests (Bogatova et al., 1997) and improved
the quality-of-life and recovery period of patients suffering from
acute non-specific pneumonia (Narimanian et al., 2005).
ADAPTOGEN EFFECTS ON G-PROTEIN SIGNALING
PHOSPHATIDYLINOSITOL AND PHOSPHOLIPASE C PATHWAYS
All tested adaptogens up-regulate the PLCB1 gene, which encodes
phosphoinositide-specific PLC and the PI3KC2G gene, which
encodes phosphatidylinositol 3-kinases (PI3Ks; Table 6; Figure 3).
When activated by a G-protein, PLC catalyses hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol
(DAG) and inositol-1,4,5-triphosphate (IP3; Figure 3; Gilman,
1987). IP3 is involved in a variety of cellular signaling pathways
associated with phenomena as diverse as depression and tumor
growth (Stutzmann, 2005; Sarkisov and Wang, 2008). DAG acti-
vates protein kinase C (PKC), which phosphorylates numerous
other proteins (Nishizuka, 1995) and plays an important role in
tumor growth (Yamasaki et al., 2009).
PI3K is a key upstream mediator of signal transduction and
plays an important role in the regulation of NF-kB-mediated
defense responses as well as apoptosis. PI3K is required for long-
term enhancement of signal transmission between neurons, which
is associated with potentiating memory and learning (Opazo et al.,
2003; Karpova et al., 2006; Yang et al., 2008).
COMMON EFFECTS ON GENE EXPRESSION INVOLVED IN REGULATION
OF CYTOPLASMATIC AND NUCLEAR PROTEINS
ADAPT-232 up-regulated the SERPINI1 gene (serpin peptidase
inhibitor, neuroserpin), which is involved in the development and
function of the nervous system (Teesalu et al., 2004; Yepes and
Lawrence, 2004). Neuroserpin controls axon growth and thereby
supports the transmission of nerve impulses. It plays an impor-
tant role in synapse development and regulates synaptic plasticity,
suggesting that it may be important for learning and memory
(Hastings et al., 1997; Davis et al., 1999; Kinghorn et al., 2006).
Moreover, neuroserpin inhibits the activity of tissue plasminogen
activator (tPA), which plays a role in cell migration, blood clotting,
and inflammation (Yepes and Lawrence, 2004).
A characteristic feature common to all tested adaptogens was
down-regulation of the CETP gene, which encodes cholesteryl
ester transfer protein, a lipid plasma protein that facilitates the
transport of cholesterol esters and triglycerides between low-
density lipoproteins (LDL) and high-density lipoproteins (HDL;
Bruce et al., 1998). Pharmacological inhibition of CETP allevi-
ated atherosclerosis and other cardiovascular diseases, as well as
metabolic syndrome (Barter et al., 2003).
Adaptogens down-regulated the ESR1 gene (Table 6). ESR1
encodes estrogen receptor alpha (ERα), a nuclear receptor belong-
ing to a large family of transcription factors, transducing hormonal
signals, and regulating expression of target genes (Evans, 1988).
ERα is primarily localized in the cytoplasm (Welshons et al.,
1984) in complexes with heat-shock-proteins (hsp90, hsp70, and
hsp56) in a transcriptionally inactive form (Pratt, 1992). ERα are
expressed in various tissues such as the breast, ovaries, testis, lung,
uterus, bone, liver, and brain. In human forebrain, ERα are pre-
dominantly localized in amygdale (suggested to be involved in
mood and cognition), hypothalamus (involved in learning and
memory), and septum (Österlund and Hurd, 2001;Yaghmaie et al.,
2005; Dahlman-Wright et al., 2006). Affective mood disorders,
such as premenstrual syndrome, postnatal depression, and post-
menopausal depression are associated with low serum-levels of
estrogens. Estradiol treatment has been shown to down-regulate
ERα in the uterus and in several brain areas (Shupnik et al., 1989;
Lauber et al., 1990, 1991; Simerly and Young, 1991; Österlund et al.,
1998).
ESR1 expression is tissue-specific and differentially regulated
in a region specific manner in the brain. It has been shown that
estrogen signaling via ERα can significantly attenuate an inflam-
matory neurodegenerative process by acting through astrocytes.
ERα expression is necessary in astrocytes, but not neurons for
neuroprotection in experimental autoimmune encephalomyelitis,
the most widely used mouse model of multiple sclerosis – an
autoimmune disease characterized by demyelination and axonal
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degeneration (Spencea et al., 2011). Consequently, it can be
expected that neuroprotective effect of adaptogens (Kim et al.,
2004; Bu et al., 2005; Chen et al., 2009a; Qu et al., 2009; Bocharov
et al., 2010; Zhang et al., 2007, 2010; Li et al., 2011; Lee et al.,
2012a,b; Palumbo et al., 2012; Shi et al., 2012; Zeng et al., 2012)
must be associated with up-regulation ESR1 in glia cells. Surpris-
ingly, the results of our study are not in line with this antici-
pation because adaptogens down-regulate ERα gene expression.
How to interpret these contradictory observations – neuroprotec-
tion accompanied by down-regulation of ERα gene expression?
This case is similar to another, when it was expected that stress-
protective adaptogens have to reduce cortisol, because normally
cortisol is increasing in stress. Indeed, adaptogens reduce corti-
sol in stress (Panossian et al., 1999b). However, adaptogens can
increase secretion of cortisol/corticosterone when added to iso-
lated adrenocortical cells (Panossian et al., 1999b; Panossian et al.,
2007). Cell response (secretion of cortisol/corticosterone) to adap-
togens and stress is similar – an activation, mild to adaptogens
and much stronger in stress. However, stress response (secretion
of cortisol/corticosterone) was significantly low in adaptogen pre-
treated cells than in control cells (Panossian et al., 1999b; Panossian
et al., 2007). Pretreatment with adaptogen, so-called “adaptive
stress response”or“preconditioning”or“hormesis”(Mattson et al.,
2007), acting as a mild stress or “stress vaccine,” adapts the cell
to stress (Panossian et al., 1999b; Wiegant et al., 2008; Boon-
Niermeijer et al., 2012). Similarly, it can be speculated that down-
regulation of ERα gene expression by adaptogens is a signal for glia
cell to initiate a feedback regulation of ERα. In a broader sense this
concept is related to the inflammation, which is a defense response
(“switch on” defense system) to cope the infection. In order to
prevent an overreaction, a feedback mechanism of regulation of
inflammation is activated, e.g., cortisol and anti-inflammatory
cytokines are increasing (“switch off” defense system). Mild stress,
in general, is a defense response in order activate innate immunity.
In this context, adaptogens are natural substances initiating acti-
vation of the innate defense systems, including ERα as one of the
component of stress system.
In addition to “classical” model of steroid receptor function,
when the ligand-bound estrogen receptor regulates transcription
of target genes in the nucleus by binding to estrogen response
element regulatory sequences in target genes, estrogen activated
membrane-bound CRα initiates rapid signaling PI3K/PLC path-
ways in astrocytes to indirectly modulate neuronal function and
survival (Deroo and Korach, 2006; Mhyre et al., 2006). Estro-
gen treatment attenuates “non-classical” transcription at estrogen
response elements sites in glioma cells (Mhyre et al., 2006). Adap-
togens up-regulate PLCB1, PI3KC2G, and cAMP relate genes,
modulate NO and SAPK. These similarities of estrogens and
adaptogens allow to suggest that their mechanisms of actions
someway interfere. Are they competing as mimetic or antago-
nists is still unclear albeit both are neuroprotective. Further study
on elucidation of this mechanism of action of adaptogens is
required.
ERs are over-expressed in around 70% of breast cancers (Deroo
and Korach, 2006). Pharmacological down-regulation of ESR1
may be effective in treatment and prevention of breast cancer,
ovarian cancer, colon cancer, prostate cancer, and endometrial
cancer. (Fabian and Kimler, 2005; Ascenzi et al., 2006).
Moreover, some of tested samples down-regulated the OLFM4
gene, which was recently reported to inhibit apoptotic path-
ways and to promote tumor cell proliferation. This suggests that
OLFM4 could serve as a diagnostic marker for human can-
cers (Koshida et al., 2007; Oh et al., 2011). Reduced expression
of the OLFM4 gene inhibits cell growth and increases sensiti-
zation to hydrogen peroxide and tumor necrosis factor alpha-
induced apoptosis in gastric cancer cells (Liu et al., 2012). Down-
regulation of the PLCD4 gene (Table 6), which encodes cyto-
plasmatic PLC, is apparently associated with catabolic activity of
adaptogens.
THE SYNERGY/ANTAGONISM CONCEPT AND CONSIDERATIONS ON
DOSE-EFFECT DEPENDENCY
The mechanism of action of adaptogens in T98G cells was
associated with deregulation of numerous genes. Even one
single compound purified from the extracts, e.g., salidroside,
triandrin, tyrosol from Rhodiola, schizandrin B from Schisan-
dra, or eleutheroside E from Eleutherococcus affected the activ-
ity of 500–700 genes belonging to several different functional
networks.
The approximate number of genes affected by any single com-
pound in ADAPT-232 was on the same order as the number of
genes affected by the entire mixture. Even if the gene expres-
sion profile contained the same genes (Figure 2), their expression
remains of the same extent (the same fold range, Tables 5 and 6
and Supplementary Material). The total number of interactions
in the molecular networks did not increase proportionally with
the number of active compounds in the mixture. Further, the
number of target genes affected by the complex mixture was
decreased in some pathways as compared to single compounds.
Figure 2 shows that 735 deregulated genes overlap between the
single-component compounds. However, they do not account for
all 1056 genes affected by ADAPT-232, suggesting that deregula-
tion of 321 genes by ADAPT-232 is due to synergic interactions.
Thus, it is possible that some of ADAPT-232’s pharmacologi-
cal effects are associated with these 321 genes, supporting the
synergy concept for herbal mixtures. On the other hand, the
complete pool of all genes deregulated by three single extracts
is 2188, while ADAPT-232 deregulates only 1056 genes. This indi-
cates that antagonistic interactions of the three components in the
mixture may result in suppression of some effects (possibly neg-
ative) of the mono-drugs in fixed combination in ADAPT-232.
This is also in line with synergy/antagonism concept for herbal
mixtures.
Purified single substances revealed differential regulation of
more genes than did the extracts, e.g., Rhodiola extract affected
more genes than salidroside, tyrosol, or triandrin, and ADAPT-232
affected more genes than Rhodiola, Schisandra, or Eleutherococcus
extracts (Tables 5 and 6).
For example, schizandrin B at a concentration of 3µM sig-
nificantly down-regulated a number of genes (up to 12854 fold,
Table 7) which were not affected in the total extract (in which
the concentration of schizandrin was comparable). Moreover,
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Table 7 |Top down-regulated genes in schisandrin B-treatedT98G cells
as investigated by Ingenuity Pathway analysis.
Symbol Description Fold change
DOWN-REGULATED GENES
XRCC6 Ku70 protein* −12854.6
RPS21 Ribosomal protein S21 −1618.0
YPEL5 Yippee-like 5 (Drosophila) −1082.4
KCTD20 Potassium channel tetramerization
domain containing 20
−252.5
DSTN Destrin (actin depolymerizing factor) −126.2
*Ku70 is a protein that, in humans, is encoded by the XRCC6 gene, which is
involved in DNA repair and chromatin remodeling. It is possible that XRCC6 is
involved in aging, although further results are necessary to determine whether
it plays this role in humans. “Entrez Gene: XRCC6 X-ray repair complementing
defective repair in Chinese hamster cells 6 (Ku autoantigen, 70 kDa).”
Table 8 |Top up-regulated genes inT98G cells treated with ADAPT-232
forte (3 mg/L) as investigated by Ingenuity Pathway analysis.
Symbol Description Fold change
UP-REGULATED GENES
GCM2 Glial cells missing homolog 2
(Drosophila)
+948.8
EPHB1 EPH receptor B1 +903.9
ALX1 ALX homeobox 1 +867.1
CHRNB4 Cholinergic receptor, nicotinic, beta 4
(neuronal)
+670.9
SF3B2 Splicing factor 3b, subunit 2, 145 kDa +652.6
WNT2B Wingless-type MMTV integration site
family, member 2B
+584.1
AICDA Activation-induced cytidine deaminase +552.6
CD37 CD37 molecule +505.0
MDFI MyoD family inhibitor +487.8
TNNT2 Troponin T type 2 (cardiac) +461.4
HSPA12B Heat shock 70 kDa protein 12B +44.0
HSPB8 Heat shock 22 kDa protein 8 +46.8
HTR5A 5-Hydroxytryptamine (serotonin)
receptor 5A, G-protein-coupled
+75.0
the gene expression profiles of schizandrin B and Schisandra
extract were quite different (Table 7). The same is true for
other compounds as shown in Tables 6–8. This data may sup-
port the reductionistic concept of drug discovery common in
“western medicine” that is based on the isolation and applica-
tion of active constituents rather than the use of complex plant
extracts.
The dose at which the compounds were administered strongly
influenced both the intensity of the cellular response and the
profile of differentially expressed genes. For instance, ADAPT-
232 forte taken at two different concentrations (3 and 300 mg/L)
resulted in quite different gene expression profiles, including some
instances of dose-dependent reversal effects on the same gene, e.g.,
the adenylate cyclase-encoding gene (Table 8).
In can be concluded that cellular sensitivity/reactivity is
decreasing at higher doses of adaptogens resulted in increased cel-
lular tolerance to other stressors. Some effects of individual ingre-
dients on gene expression were neutralized when the ingredients
were combined in mixtures. In general, only the most common
effects attributed to the individual ingredients were observed in
the complex mixtures. Interestingly, rather than potentiating gene
expression levels, the combination of these components resulted
in somewhat of a “smoothing effect” on gene expression level.
The limitations of any in virto cell models experiment obvi-
ously should be considered when conclusions are generalized. The
changes in gene profile of any isolated cell line can not reflect all of
those in entire organism, because of numerous interactions with
circulating hormones and mediators of immune system. However,
these in vitro experiments can be helpful in finding of possible key
mechanisms of action of adaptogens, particularly when they are
considered in the context of huge body of evidences obtained in
clinical and preclinical studies. It is just the first step in order
to define a realistic hypothesis. Further studies can be focused
on evidences supporting this hypothesis. It is not excluded that
plant extracts are metabolized in the liver thus, their metabo-
lites may also compete with precursors. However, relevance of
this in vitro model to the results of clinical studies is supported
by pharmacokinetic studies of salidroside, tyrosol, eleutheroside
E, and schizandrin. The half-life (t 1/2) was 4.662 h for eleuthero-
side E (Feng et al., 2006), 4.5 h for salidroside in SHR-5 extract
(Panossian et al., 2010), 2 h for tyrosol (Panossian et al., 2009),
and 4.6 h for schizandrin (Wang et al., 2008). Pharmacokinetic
curve of schizandrin has three maximums of concentration s in
blood at 1, 3, and 8 h and it is still detectable in blood at least for
20 h (Wang et al., 2008; Liang et al., 2010). That is enough to reach
brain from the bloodstream, to pass the blood-brain barrier and to
interact with membranes of glial cells, where G-protein receptors
are located.
In conclusion, the effects of adaptogens on gene expression
profiles in neuroglial cells mainly affected energy metabolism
(anabolic effects) and CNS functions. These results can be recon-
ciled with beneficial effects of adaptogens in behavioral, mental,
and aging-related disorders.
We conclude also, that blending two or more active substances
in one mixture significantly changes deregulated genes profiles:
synergetic interactions result in activation of genes that none of
the individual substances affected, while antagonistic interactions
result in suppression some genes activated by individual sub-
stances. Consequently, these changes can have an influence on
transcriptional control of metabolic regulation both on the cel-
lular level and the level of the whole organism. As a result, the
pharmacological profile of the combination may differ from the
profiles of the ingredients. Similarly, pharmacological profiles of
purified compounds might differ from the pharmacological pro-
file the total plant extract. Presumably, this phenomenon could
be used to eliminate undesirable effects (e.g., toxic effects) and
increase the selectivity of pharmacological intervention.
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